Diabetic Kidney Disease
Conditions
Keywords
Shenxiao Yuning Decoction, Diabetic Kidney Disease
Brief summary
To explore the therapeutic effect of Shenxiao Yuning Decoction on albuminuria and the improvement of traditional Chinese medicine syndrome in patients with stage III diabetic kidney disease with Qi and Yin deficiency and blood stasis syndrome.
Interventions
DRUGShenxiao Yuning decoction
Astragalus 30g, Radix Pseudostellariae 15g, Rehmannia glutinosa 15g, Rhodiola rosea 12g，Cimicifuga 15g，Cuttlebone 15g，Poria 15g，Cicada degeneration 9g，Rheum palmatum 6g.
(i) Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; (ii) control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure >140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.
Sponsors
Lin Liao
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Meet the diagnostic criteria for albuminuria in type 2 diabetic nephropathy, persistent albuminuria, and 2 consecutive urine microalbumin/creatinine (ACR) \>30mg/g within 3 months; * The glomerular filtration rate eGPR ≥ 60ml/min/1.73m2, and is required to remain stable during the trial (eGFR decreases ≤25% from the beginning of screening to the second week of follow-up); * Those who are consistent with the syndrome of diabetes and kidney disease, deficiency of Qi and Yin and blood stasis; * Gender is not limited, age is 18-75 years old, BMI≤45 kg/m2; * Glycated hemoglobin (HbA1C) 6-11%, fasting blood glucose (FPG) ≤15 mmol/L; * Systolic blood pressure/diastolic blood pressure (SBP/DBP) ≤180/100 mmhg (sitting); * Those who have complete medical records, voluntarily participate in this clinical study, and sign the informed consent form.
Exclusion criteria
* Pregnant and lactating women; * Acute complications of diabetes such as hypoglycemic coma, diabetic ketosis, lactic acidosis, etc. have recently occurred; * Those combined with heart failure and myocardial infarction; combined with infections, immune diseases, and malignant tumors; combined with liver diseases (ALT, AST or ALP levels exceed three times the upper limit of normal); * Male serum creatinine (SCr) ≥1.50 mg/d1 (114.4 μmol/L), or female serum creatinine ≥1.40 mg/dl (106.8 μmol/L); * Those who are combined with other kidney and renovascular diseases, or those who have other causes such as excessive exercise, heart failure, febrile infections, or urinary tract infections that lead to elevated urinary microalbumin; * Those who have used nephrotoxic drugs and antioxidants, or used systemic glucocorticoid therapy in the past 2 weeks; * Those undergoing dialysis or kidney transplantation; * History of bariatric surgery or other gastrointestinal surgery causing chronic malabsorption within 2 years; * Persons with drug contraindications: pregnant or lactating women, allergic constitutions, and those allergic to the drugs used in this study; * Those who are unable to cooperate due to severe mental illness or mental disorder; * Those who have not signed the informed consent form.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effective rate | 0 week，4 weeks | Clinical control: Urine routine examination of urine protein qualitative turn negative, ACR normal. Apparent effect: ACR reduction ≥50%. Effective: ACR reduction ≥15%, but less than ≥50%. Ineffective No improvement in clinical manifestations and laboratory parameters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Urinary β2-MG | 0 week，4 weeks | Collect random urine measurements from patients Urinary β2-MG |
| Scr | 0 week，4 weeks | Collect the patient's fasting blood to measure Scr |
| BUN | 0 week，4 weeks | Collect the patient's fasting blood to measure BUN |
| uric acid | 0 week，4 weeks | Collect the patient's fasting blood to measure uric acid |
| Cys-C | 0 week，4 weeks | Collect the patient's fasting blood to measure Cys-C |
| fasting plasma glucose | 0 week，4 weeks | Collect the patient's fasting blood to measure fasting plasma glucose |
| Urinary α1-MG | 0 week，4 weeks | Charge patients for random urine measurements Urinary α1-MG |
| total cholesterol | 0 week，4 weeks | Collect the patient's fasting blood to measure total cholesterol |
| Triglyceride | 0 week，4 weeks | Collect the patient's fasting blood to measure Triglyceride |
| HDL | 0 week，4 weeks | Collect the patient's fasting blood to measure HDL |
| LDL | 0 week，4 weeks | Collect the patient's fasting blood to measure LDL |
| albumin | 0 week，4 weeks | Collect the patient's fasting blood to measure albumin |
| Urinary microalbumin/urinary creatinine | 0 week，4 weeks | Collect random urine samples from patients to measure urine microalbumin/urinary creatinine（mg/g） |
| HbA1c | 0 week，4 weeks | Collect the patient's fasting blood to measure HbA1c |
Countries
China
Outcome results
None listed